Status:
RECRUITING
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Lead Sponsor:
Accession Therapeutics Limited
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus del...
Eligibility Criteria
Inclusion
- Consenting male and female adults (18 years of age) with select solid epithelial tumour indications known to have high frequency (75 percent) of αvβ6 integrin receptor expression as detailed in the applicable SP.
- Received and failed/intolerant of Standard of Care (SoC) therapy where eligible (not including neoadjuvant).
- Tumour lesion (not previously irradiated), suitable for safe pre- and post-treatment biopsies.
- Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
- Minimum life expectancy anticipated to be greater than three months
- Willing to undertake appropriate measures of hygiene to prevent any spread of virus and protection of vulnerable individuals.
- Adequate organ function.
- Compliant with requirements for prior treatment washout and contraceptive measures applicable to genetically modified organisms (GMOs) and cancer therapies
- Prior immune checkpoint antibody therapies as single agents or in combination with other anti-cancer agents is permissible.
Exclusion
- Significant degree of fibrotic disease, including autoimmune diseases (e.g. systemic lupus, rheumatoid arthritis) or idiopathic and occupation-related pulmonary fibrosis.
- Known prior history of intolerance to anti-programmed cell death protein 1 (PD-1) and/or anti-PD-L1 immunotherapy due to toxicity.
- Has any of the comorbid conditions listed in the detailed protocol exclusion criteria.
Key Trial Info
Start Date :
March 21 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2034
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06977737
Start Date
March 21 2025
End Date
December 31 2034
Last Update
December 8 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
START Barcelona
Barcelona, Spain
2
Start Fjd
Madrid, Spain
3
Start Hm Ciocc
Madrid, Spain
4
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom